Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 18/20 | 0.71 |
| ▸ | HTR2A | P28223 | 12/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3134684 | 0.86 | SLC6A4 (0.75) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL20852556 | 0.85 | SLC6A4 (0.73) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL19361290 | 0.85 | SLC6A4 (0.73) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL6947509 | 0.83 | SLC6A4 (0.71) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL6152176 | 0.81 | SLC6A4 (0.68) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL22910542 | 0.80 | SLC6A4 (0.67) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL6152090 | 0.80 | SLC6A4 (0.66) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL6151984 | 0.80 | SLC6A4 (0.66) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL18401370 | 0.77 | SLC6A4 (0.75) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL3842045 | 0.75 | ALDH1A1 (0.58) | SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200397927-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2020-12-24 | — | — | US | disclosed |
| US-20170266326-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170266326-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | FABP3, TNNI3, TNNT2 | SLC6A4 229/4885HTR2A 562/4885KCNH2 2249/4885 |
| US-20200397927-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | FABP3, TNNI3, TNNT2 | SLC6A4 229/4885HTR2A 562/4885KCNH2 2249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.